Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised trial of BI 690517 with or without empagliflozin in chronic kidney disease
jRCT2031210597Phase 2Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of vicadrostat in chronic kidney disease (CKD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from treatment period baseline in log-transformed UACR. Started Feb 2022; status: recruiting.
02
Drugs
vicadrostat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2031210597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210597.